Grimes & Company Inc. Purchases 691 Shares of SPDR S&P Biotech ETF (NYSEARCA:XBI)

Grimes & Company Inc. lifted its position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 33.0% during the 4th quarter, HoldingsChannel reports. The firm owned 2,784 shares of the exchange traded fund’s stock after acquiring an additional 691 shares during the period. Grimes & Company Inc.’s holdings in SPDR S&P Biotech ETF were worth $251,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in XBI. Hartline Investment Corp increased its stake in shares of SPDR S&P Biotech ETF by 2.0% during the third quarter. Hartline Investment Corp now owns 5,502 shares of the exchange traded fund’s stock valued at $544,000 after purchasing an additional 106 shares in the last quarter. Signature Estate & Investment Advisors LLC increased its position in SPDR S&P Biotech ETF by 5.7% during the 3rd quarter. Signature Estate & Investment Advisors LLC now owns 2,336 shares of the exchange traded fund’s stock valued at $231,000 after buying an additional 125 shares in the last quarter. Denver Wealth Management Inc. increased its position in SPDR S&P Biotech ETF by 0.9% during the 3rd quarter. Denver Wealth Management Inc. now owns 14,779 shares of the exchange traded fund’s stock valued at $1,460,000 after buying an additional 127 shares in the last quarter. Trust Co. of Vermont boosted its holdings in SPDR S&P Biotech ETF by 4.7% in the third quarter. Trust Co. of Vermont now owns 3,058 shares of the exchange traded fund’s stock worth $302,000 after acquiring an additional 138 shares in the last quarter. Finally, Graypoint LLC grew its stake in shares of SPDR S&P Biotech ETF by 5.6% in the third quarter. Graypoint LLC now owns 2,738 shares of the exchange traded fund’s stock worth $271,000 after acquiring an additional 146 shares during the last quarter.

SPDR S&P Biotech ETF Price Performance

Shares of NYSEARCA:XBI opened at $92.46 on Monday. The company has a market capitalization of $7.05 billion, a PE ratio of 11.47 and a beta of 1.11. The business has a fifty day moving average price of $93.34 and a 200-day moving average price of $96.90. SPDR S&P Biotech ETF has a 1-year low of $81.14 and a 1-year high of $105.47.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.